Trial Profile
Confirmatory Study of DSP-5423P in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Blonanserin (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma; Sumitomo Pharma
- 18 Jun 2019 According to a Sumitomo Dainippon Pharma media release, the new drug application for a transdermal patch formulation of atypical antipsychotic LONASEN Tape 20 mg, 30 mg, and 40 mg (blonanserin) has been approved in Japan.
- 10 May 2019 Status changed from active, no longer recruiting to completed.
- 10 Sep 2018 According to a Sumitomo Dainippon Pharma media release, data from this trial were presented in a poster presentation at WFSPB 2018 KOBE (WFSBP Asia Pacific Regional Congress of Biological Psychiatry)